Powered by

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn into Oncology

Aug 06, 2019 - GlobeNewswire

VANCOUVER, Washington, Aug. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the injection of the first patient with metastatic triple-negative breast cancer ("mTNBC").  The patient will be treated with leronlimab by Jacob Lalezari, M.D., currently Chief Executive Officer of Quest Clinical Research...